AstraZeneca India has reported impressive financial results for Q2 FY24, reflecting significant improvements in revenue, profitability, and efficiency. The company’s EBITDA surged by 61%, with a 240 basis points (bps) year-over-year (YoY) margin increase, underscoring its focus on operational performance.
Key Financial Highlights for Q2 FY24:
- Revenue from Operations: Increased to ₹408 crore, up 5.3% from ₹387.5 crore in Q1 FY24.
- Profit Before Exceptional Item and Tax: Reached ₹51 crore, marking a rise from ₹42.4 crore in the previous quarter, demonstrating enhanced operational efficiency.
- Profit After Tax (PAT): Achieved a profit of ₹38.4 crore in Q2 FY24, a turnaround from the loss of ₹11.8 crore in Q1 FY24, significantly improving the bottom line.
Half-Year Performance (H1 FY24):
- Cumulative Revenue: ₹795.5 crore.
- Profit Before Tax: ₹93.4 crore.
- Profit After Tax: ₹26.6 crore, reflecting a solid recovery trajectory.
AstraZeneca’s robust Q2 performance highlights its commitment to profitable growth and operational efficiency. With notable improvements in revenue and profitability metrics, AstraZeneca remains a compelling stock to watch in the healthcare sector as it continues to strengthen its market position.
